• No results found

Matrix metalloproteinases in inflammatory bowel disease : expression, regulation and clinical relevance Meijer, M.J.W.

N/A
N/A
Protected

Academic year: 2021

Share "Matrix metalloproteinases in inflammatory bowel disease : expression, regulation and clinical relevance Meijer, M.J.W."

Copied!
9
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

Matrix metalloproteinases in inflammatory bowel disease : expression, regulation and clinical relevance

Meijer, M.J.W.

Citation

Meijer, M. J. W. (2009, April 23). Matrix metalloproteinases in inflammatory bowel disease : expression, regulation and clinical relevance. Retrieved from https://hdl.handle.net/1887/13749

Version: Corrected Publisher’s Version

License: Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden

Downloaded from: https://hdl.handle.net/1887/13749

Note: To cite this publication please use the final published version (if

applicable).

(2)

Matrix Metalloproteinases in Inflammatory Bowel Disease

Expression, Regulation and Clinical Relevance

Martin Jan-Willem Meijer

(3)



ISBN: 978-90-9024077-0

Printed by Gildeprint Drukkerijen B.V., Enschede, The Netherlands

© M.J.W. Meijer, Zeist 2009

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical including photocopy, recording or any information storage and retrieval system, without prior written permission from the author.

The work described in this thesis was performed at the Department of Gastroenterology and Hepatology of the Leiden University Medical Center (Leiden, The Netherlands). The project was partly financed by a grant from the Netherlands Digestive Diseases Foundation (WS 98-17)

Printing of this thesis was financially supported by the Section Experimental Gastroenterology (SEG) of the Netherlands Society of Gastroenterology (NVGE).

(4)

Matrix Metalloproteinases in Inflammatory Bowel Disease

Expression, Regulation and Clinical Relevance

PROEFSCHRIFT

ter verkrijging van de graad van Doctor aan de Universiteit Leiden, op gezag van Rector Magnificus prof. mr. P.F. van der Heijden,

volgens besluit van het College voor Promoties te verdedigen op donderdag 23 april 2009

klokke 16.15 uur

door

Martin Jan-Willem Meijer geboren te Amsterdam

in 1974

(5)



Promotiecommissie :

Promoter: Prof. dr. C.B.H.W. Lamers Co-promoter: Dr. ir. H.W. Verspaget

Referent: Prof. dr. A.S. Peña, Vrije Universiteit Amsterdam Overige leden: Prof. dr. A. van der Laarse

Prof. dr. P.H.A. Quax

Prof. dr. D.W. Hommes

Dr. R.A. van Hogezand

(6)

Contents

Abbreviations 7

Chapter 1 Introduction

9

Chapter 2

Expression of matrix metalloproteinases-2 and -9 in intestinal tissue of patients with inflammatory bowel disease (IBD)

Dig Liver Dis 2005; 37: 584-592

57

Chapter 3

Effect of the anti-tumor necrosis factor-Į antibody infliximab on the ex vivo mucosal matrix metalloproteinase-proteolytic phenotype in inflammatory bowel disease (IBD)

Inflamm Bowel Dis 2007; 13: 200-210

79

Chapter 4

Infliximab treatment influences the serological expression of matrix metalloproteinase (MMP)-2 and-9 in Crohn’s disease Inflamm Bowel Dis 2007; 13: 693-702

111

Chapter 5

Increased mucosal matrix metalloproteinase-1, -2, -3 and -9 activity in patients with inflammatory bowel disease and the relation with Crohn’s disease phenotype

Dig Liver Dis 2007; 39: 733-739

135

Chapter 6

Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and tumor necrosis factor-Į single nucleotide gene polymorphisms in inflammatory bowel disease

World J Gastroenterol 2007; 13: 2960-2966



153

Chapter 7

Matrix metalloproteinases and their tissue inhibitors as prognostic indicators for diagnostic and surgical recurrence in Crohn’s disease Inflamm Bowel Dis 2009; 15: 84-92

173

Chapter 8

Summarizing discussion

193

Chapter 9

Nederlandse samenvatting Nawoord

Curriculum vitae

209

(7)



(8)

Abbreviations

APMA p-amino-phenyl-mercuric acetate

ARMS Amplification refractory mutational system BIA Bio-immuno activity assay

CD Crohn’s disease CI Confidence interval CRC Colorectal carcinoma DSS Dextran sodium sulphate ECM Extracellular matrix

ELISA Enzyme-linked immunosorbent assay HR Hazard ratio

IBD Inflammatory bowel disease IFN Interferon

IL Interleukin

HRP Horse radish peroxidase kDa Kilo Dalton

LPS Lipopolysaccharide MMP Matrix metalloproteinase MPO Myeloperoxidase NS Not significant

PMNL Polymorphonuclear leukocyte PWM Pokeweed mitogen

RFLP Restriction fragment length polymorphism RT-PCR Reverse transcription polymerase chain reaction SEM Standard error of the mean

SNP Single nucleotide polymorphism TGF Transforming growth factor

TIMP Tissue inhibitor of metalloproteinases TNF Tumor necrosis factor

UC Ulcerative colitis

(9)



Referenties

GERELATEERDE DOCUMENTEN

Matrix metalloproteinases (MMP) and the tissue inhibitors of metalloproteinases (TIMP) are involved in the (etio)pathogenesis of CD and may thereby also affect

License: Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden Downloaded.

Expression and regulation of tissue inhibitor of metalloproteinase-1 and matrix metalloproteinases by intestinal myofibroblasts in inflammatory bowel disease.. Roderfeld

Matrix metalloproteinase-2 and more strongly matrix metalloproteinase-9 protein and mRNA were markedly increased in inflammatory bowel disease tissues, with the highest levels

10 A marked upregulation of MMP-1, -2, -3, -7, -9,-10, -12, -13, and -14 mRNA and/or (active) protein levels has been demonstrated in the intestinal mucosa of IBD patients,

In contrast to the serum levels of MMP-2, MMP-9 levels in patients with fistulas from the international study showed a trend to decrease in all groups during the follow-up, with

Expression of total levels of matrix metalloproteinases-1, -2, -3 and -9 relative to tissue inhibitor of metalloproteinases-1 and -2 was increased in inflamed inflammatory bowel

To study the (functional) relevance of single nucleotide polymorphisms (SNPs) in genes encoding matrix metalloproteinases (MMP)-1, -2, -3, -9, tissue inhibitors of